Clinical research is often the backbone of modern medicine, and without it, healthcare simply wouldn’t exist like it does today. Because it is known to analyze participants in order to understand their health conditions and diseases, the goal of it is to find better ways to prevent, diagnose, and manage illnesses in hopes of advancing overall human health.
Even still, there’s hurdles that come with each clinical trial space. Many today do not reflect diverse populations, raising critical questions about whether medicines and therapies developed through research will work effectively for everyone. According to recent data, the need for diversity in clinical trial participation is urgently rising.
The growing body of data shows that racial and ethnic minorities comprise 39% of the U.S. population but only account for 2-16% of clinical trial participants. While around 14% of Americans are Black, they account for less than 5% of trial participants. At the same time, Latinos only represent about 1% of the clinical trial pool, and this lack of diversity is similarly poor in other countries.
When trials fail to include people with varied cultures, genetics, and lifestyles, the consequences become deeply concerning. Researchers may miss crucial differences in how a drug works or doesn’t work among various groups. Clinical research that does not consider every kind of person can also produce skewed data, eroding both the validity of findings and the equity of medical care.
As AXIS Clinicals CEO, Dinkar Sindhu adds, “Genetic, metabolic, and environmental differences across populations can significantly influence how patients respond to investigational therapies, especially in rare disease trials. Maintaining a diverse and equitable pool of human trial participants is vital, especially in rare disease research, because treatments developed from homogeneous cohorts may not work effectively across different genders, ethnicities, ages, or disability statuses.”
Among other implications, when people from minority groups are underrepresented in research, they may be less likely to benefit or gain access to promising medicine. Over time, this kind of gap can lead to communal mistrust across surrounding communities.
Sindhu continues to say that, “Without representation that mirrors real‑world patient communities, we risk producing therapies that leave many groups unserved or misunderstood.”
If diversity is a real-world problem, clinical sponsors must address this not only to enhance medicine, but to ensure meaningful results do not go unnoticed.
Industry experts might argue the first step to removing this barrier is acknowledging the factors that keep underrepresented groups from enrolling in the first place. This involves recognizing where the inaccessibility may lie, whether that means costs, transportation, scheduling, or timing. For instance, trials that require excessive stays or frequent travel can likely exclude those of rural areas, people with lower incomes, or those with busy work lives.
Clinical sponsors can also invest in community engagement groups that already have established trust within diverse communities. Building this level of partnership can enable researchers to connect with different kinds of people, ultimately strengthening communication and networking strategies.
Employing diverse clinical staff is another way to leverage holistic participation. When research coordinators, investigators, and outreach teams reflect populations they are trying to recruit, potential candidates may feel more understood and respected. Having a familiar face develops cultural understanding that can lower fears of skepticism and uncertainty.
For clinical trials willing to make research more inclusive, the overarching impact could extend far beyond new medicine alone. Diverse trials can increase enrollment speed, reduce safety risks, and produce more output in the long run. From an ethical standpoint, more representative research also means an opportunity for all people, regardless of background, to voice how they want care to be shaped.
In the United States, much work has been done to improve diversification, yet there’s still a lot to resolve before early-phase research can move in the right direction. But while most clinical trials fail to mimic racial and ethnic groups fully, there’s at least some momentum and attention in this area.
At best, while progress will not happen overnight, the sponsors that can take small, proactive steps now will be the ones to maintain trial success. As medicine continues to develop, let’s hope every clinical study can start to realize what kind of treatment works for everyone.
Alex Hamilton